LPCN

Lipocine Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↓ 3/10
  • Momentum↑ 9/10
Lipocine sales and earnings growth
LPCN Growth
Neutral
  • Revenue Y/Y↓ -45.44%
  • EPS Y/Y↓ -37.84%
  • FCF Y/Y↓ -2.28%
Lipocine gross and profit margin trends
LPCN Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -126.70%
  • ROIC↓ -42.10%
Lipocine net debt vs free cash flow
LPCN Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Lipocine stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗